TransCode Therapeutics, Inc. (RNAZ)
NASDAQ: RNAZ · Real-Time Price · USD
0.515
+0.035 (7.29%)
At close: Nov 4, 2024, 4:00 PM
0.530
+0.015 (2.91%)
Pre-market: Nov 5, 2024, 7:08 AM EST
TransCode Therapeutics Ratios and Metrics
Market cap in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| Current | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
| Nov '24 Nov 4, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 |
| Market Capitalization | 9 | 4 | 9 | 33 | - | - | |
| Market Cap Growth | 76.26% | -52.64% | -73.32% | - | - | - | |
| Enterprise Value | 6 | -3 | -0 | 10 | - | - | |
| Last Close Price | 0.52 | 6.59 | 538.40 | 2032.00 | - | - | |
| PE Ratio | - | -0.06 | -0.50 | -3.13 | - | - | |
| PB Ratio | 2.83 | 2.52 | 2.69 | 1.60 | - | - | |
| P/FCF Ratio | -0.47 | -0.23 | -0.55 | -5.93 | - | - | |
| P/OCF Ratio | -0.47 | -0.23 | -0.55 | -6.21 | - | - | |
| EV/EBITDA Ratio | -0.15 | 0.14 | 0.00 | -1.67 | - | - | |
| EV/EBIT Ratio | -0.15 | 0.14 | 0.00 | -1.66 | - | - | |
| EV/FCF Ratio | -0.18 | 0.15 | 0.00 | -1.85 | - | - | |
| Debt / Equity Ratio | 0.17 | 0.27 | - | - | -0.61 | -0.84 | |
| Debt / FCF Ratio | -0.01 | -0.02 | - | - | -4.23 | -1.82 | |
| Quick Ratio | 0.96 | 0.79 | 1.15 | 8.22 | 2.05 | 3.25 | |
| Current Ratio | 1.25 | 1.28 | 1.70 | 8.97 | 2.05 | 3.25 | |
| Return on Equity (ROE) | -1048.70% | -759.85% | -148.57% | -80.53% | - | - | |
| Return on Assets (ROA) | -207.95% | -190.26% | -76.30% | -32.05% | -72.09% | -136.26% | |
| Return on Capital (ROIC) | -611.30% | -455.23% | -98.51% | -40.29% | - | - | |
| Earnings Yield | -201.37% | -448.40% | -201.12% | -20.91% | - | - | |
| FCF Yield | -173.86% | -437.86% | -181.64% | -16.87% | - | - | |
| Buyback Yield / Dilution | -15673.51% | -1003.48% | -54.03% | - | - | - | |
| Total Shareholder Return | -15673.51% | -1003.48% | -54.03% | - | - | - | |
Source: S&P Capital IQ. Standard template.
Financial Sources.